天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Methyldopa EP Impurity C
Methyldopa EP Impurity C
  • Methyldopa EP Impurity C
  • Methyldopa EP Impurity C
  • Methyldopa EP Impurity C
  • Methyldopa EP Impurity C
  • Methyldopa EP Impurity C

Methyldopa EP Impurity C NEW

Price Get Latest Price
Package 10mg 30mg 50mg
Min. Order: 10mg
Supply Ability: 10000000
Update Time: 2025-06-09

Product Details

Product Name: Methyldopa EP Impurity C CAS No.: 39948-18-0
Min. Order: 10mg Purity: 95%+
Supply Ability: 10000000 Release date: 2025/06/09

Methyldopa EP Impurity C 39948-18-0



Article illustration


Product Number: M044011
English Name: Methyldopa EP Impurity C
English Alias: (S)-2-amino-3-(3,4-dimethoxyphenyl)-2-methylpropanoic acid
CAS Number: 39948-18-0
Molecular Formula: C??H??NO?
Molecular Weight: 239.27

Product Advantages

  • High purity and structural confirmation:HPLC purity ≥99.0%, verified by multiple methods including 1H NMR, 13C NMR, IR, and elemental analysis, meeting the requirements of pharmacopoeias such as EP and USP for impurity reference standards.

  • Excellent stability:Stable for 24 months when stored at 2-8°C in the dark, with a degradation rate <1% after 7 days at room temperature in solution (e.g., methanol-water system), suitable for long-term quality monitoring.

  • Well-defined chirality:As an (S)-configured impurity, it precisely matches the chiral impurity detection needs of methyldopa APIs, avoiding result deviations caused by racemic mixture interference.


Applications

  • Pharmaceutical quality control:Used for HPLC or LC-MS detection of Impurity C in methyldopa APIs and formulations, controlling its content ≤0.3% in accordance with EP standards to ensure chiral impurities comply with ICH Q3A requirements.

  • Chiral synthesis process optimization:In the asymmetric synthesis of methyldopa, monitoring impurity content (e.g., reducing impurity from 1.2% to 0.2% when chiral catalyst dosage increases from 0.5mol% to 1.0mol%) optimizes reaction conditions to reduce diastereomer formation.

  • Analytical method development:Serves as a chiral reference standard for establishing specific detection methods, such as normal-phase HPLC using a Chiralpak IA column (250×4.6mm) to achieve baseline separation of enantiomers.

  • Toxicological research support:Provides standards for evaluating biological activity differences of chiral impurities, facilitating toxicity comparison studies of different configurations to meet regulatory requirements for stereoisomer safety assessment.


Background Description
Methyldopa EP Impurity C is a chiral impurity introduced during methyldopa (an antihypertensive drug) synthesis due to incomplete chiral center construction or isomerization reactions. This impurity has a similar structure to the parent drug but different configuration, potentially affecting drug pharmacokinetics and efficacy, or even causing specific toxic reactions. According to EP pharmacopoeia and ICH Q6A guidelines, chiral drugs require strict control of enantiomeric impurities, making accurate detection and quantification of this impurity a key aspect of methyldopa quality research.

Research Status

  • Advances in detection technology:The mainstream method is chiral HPLC using polysaccharide-based chiral columns (e.g., Chiralcel OD-H), with n-hexane-ethanol-diethylamine (80:20:0.1, v/v) as the mobile phase, detection wavelength at 220nm, and a limit of quantitation (LOQ) of 0.05%. LC-MS/MS combined with chiral ion-pair reagents can reduce the detection limit to 0.1μg/mL.

  • Formation mechanism research:This impurity mainly originates from insufficient chiral induction efficiency in α-methylation reactions. Impurity formation increases significantly at reaction temperatures above 0°C or when using achiral solvents (e.g., toluene). Using low-temperature (-20°C) chiral auxiliaries (e.g., diethyl tartrate) in the reaction can reduce impurity content to below 0.1%.

  • Safety evaluation:In vitro receptor binding assays show that the impurity has only 15% of the affinity for dopamine receptors compared to the parent drug, but rat pharmacokinetic studies indicate a 2-fold prolonged elimination half-life, suggesting that reasonable limits (e.g., EP-recommended ≤0.3%) should be set based on exposure levels.




Article illustration






Company Profile Introduction

1. Drug standards and drug impurity reference substances: provide more than 20,000 kinds of spot impurity reference substances, with sufficient supply and same-day delivery. We have a professional R&D team and comprehensive quality control testing to ensure product quality and reliability. 2. Customized synthesis of impurities and new molecules: Quickly respond to the customized needs of CDE impurities, stably supply impurities that have established quality standards, and provide customized synthesis services for new compounds in the research and development of innovative drugs. 3. Preparation and separation of unknown impurities: With a professional impurity preparation and separation technical team and SFC preparation and separation instruments, we can solve the problems of impurity preparation in complex projects. 4. Process development of new drug intermediates: provide the supply of new drugs and new molecular impurities, process optimization services, as well as the screening and impurity analysis of commercialization routes. 5. Peptide synthesis: Provide customized peptide synthesis services, and cover all kinds of degradation impurities and process impurities generated in the research and development of peptide drugs. At the same time, it provides comprehensive structural confirmation data and customized testing services.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-08-08
$0.00/5mg
VIP1Y
Guangzhou Tosun Pharmaceutical Ltd
2025-02-10
$62.00/10mg
VIP5Y
TargetMol Chemicals Inc.
2025-04-27
INQUIRY